» Articles » PMID: 29626048

Dabigatran Persistence and Adherence in New Zealand: a Nationwide Retrospective Observational Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2018 Apr 8
PMID 29626048
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effect of age and gender on persistence and adherence in patients taking dabigatran for atrial fibrillation.

Design: A retrospective observational study over 4 years using refill prescription data from the National Pharmaceutical Database.

Setting: All patients in New Zealand who received dabigatran from July 2011 to September 2015.

Population: 43 339 people filled at least one prescription of dabigatran.

Main Outcome Measures: The proportion of patients with good adherence (treatment available at least 80% of the time), and the proportion at risk of thrombosis (a break in treatment of more than 2 days) measured 6-monthly for 3 years. Medication persistence recorded over 3 years.

Results: Persistence was highest in older patients and showed a significant correlation with age (p<0.001); 24% over 70 years had discontinued treatment by 6 months compared with 50% under 50 years. Adherence was highest in the elderly (p<0.001) with 90% of patients over 80 years with good adherence at 12 months compared with 70% in patients aged 50-60 years and less than 60% in those under 50 years. The time at risk of thrombosis showed a similar pattern with 25% below 60 years with inadequate anticoagulation more than 20% of the time. Adherence dropped during the first 18 months of treatment with the most marked fall in those under 50 years. Adherence shows that breaks in treatment are common with 30% of men under 60 years with a break in treatment of at least 28 days during the first 12 months.

Conclusion: Adherence and persistence correlate with the patient's age. Those over 70 years have high adherence consistent over time whereas younger patients have significantly worse adherence which declines over the first 18 months, with the lowest rate in those under 50 years. Adherence in our study is lower than reported in clinical trials, therefore the benefit of dabigatran in stroke prevention may not be realised in clinical practice especially in younger patients.

Citing Articles

Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry.

Schulz A, Herrmann E, Ott O, Lindhoff-Last E J Clin Med. 2022; 11(16).

PMID: 36013082 PMC: 9409774. DOI: 10.3390/jcm11164845.


Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?.

Toorop M, Chen Q, Kruip M, van der Meer F, Nierman M, Faber L J Thromb Haemost. 2021; 20(2):339-352.

PMID: 34779140 PMC: 9299168. DOI: 10.1111/jth.15592.


Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.

Charlton A, Vidal X, Sabate M, Bailarin E, Martinez L, Ibanez L J Manag Care Spec Pharm. 2021; 27(9):1210-1220.

PMID: 34464214 PMC: 10391044. DOI: 10.18553/jmcp.2021.27.9.1210.


Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.

Toorop M, Chen Q, Tichelaar V, Cannegieter S, Lijfering W Eur Heart J. 2021; 42(40):4126-4137.

PMID: 34269375 PMC: 8530535. DOI: 10.1093/eurheartj/ehab421.


World Heart Federation Roadmap on Atrial Fibrillation - A 2020 Update.

Freedman B, Hindricks G, Banerjee A, Baranchuk A, Ching C, Du X Glob Heart. 2021; 16(1):41.

PMID: 34211827 PMC: 8162289. DOI: 10.5334/gh.1023.


References
1.
Brown T, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M . Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012; 18(5):351-62. PMC: 10437571. DOI: 10.18553/jmcp.2012.18.5.351. View

2.
Shore S, Carey E, Turakhia M, Jackevicius C, Cunningham F, Pilote L . Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014; 167(6):810-7. PMC: 5381802. DOI: 10.1016/j.ahj.2014.03.023. View

3.
Krueger K, Botermann L, Schorr S, Griese-Mammen N, Laufs U, Schulz M . Age-related medication adherence in patients with chronic heart failure: A systematic literature review. Int J Cardiol. 2015; 184:728-735. DOI: 10.1016/j.ijcard.2015.03.042. View

4.
Naderi S, Bestwick J, Wald D . Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012; 125(9):882-7.e1. DOI: 10.1016/j.amjmed.2011.12.013. View

5.
Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View